Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An observational study to describe the clinical impact (seizure freedom for 12 months) of clobazm (Frisium) as an adjunct therapy in patients who are not adequately stabilized with their anticonvulsant monotherapy - ADD ON

Trial Profile

An observational study to describe the clinical impact (seizure freedom for 12 months) of clobazm (Frisium) as an adjunct therapy in patients who are not adequately stabilized with their anticonvulsant monotherapy - ADD ON

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 14 Dec 2018

At a glance

  • Drugs Clobazam (Primary)
  • Indications Epilepsy
  • Focus Therapeutic Use
  • Acronyms ADD ON
  • Sponsors Sanofi
  • Most Recent Events

    • 22 Jun 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top